Business Context and Reporting Period
This Form 8-K Current Report was filed by Relmada Therapeutics, Inc. on January 12, 2023. The filing reports the appointment of a new director and the execution of related compensatory agreements.
Key Financial Metrics
The filing does not provide revenue, profit, cash flow, margin, debt, or liquidity metrics. The financial data presented is limited to the compensation terms for the newly appointed director:
- Annual Director Cash Fee: $66,000
- Audit Committee Fee: $9,900 per year
- Compensation Committee Fee: $7,700 per year
- Stock Option Grant: 200,000 shares
- Option Exercise Price: $4.22 per share
Material Changes
The primary material change reported is the expansion of the Board of Directors:
- The Board size was increased from five to six members.
- Fabiana Fedeli was appointed as a Class I Director, serving until the 2025 annual meeting.
- Ms. Fedeli was appointed to the Audit Committee and the Compensation Committee.
- The Board determined Ms. Fedeli qualifies as an "independent" director under SEC and Nasdaq rules.
Guidance, Outlook, and Risks
The filing contains no financial guidance, outlook, or management commentary regarding business operations. The following contingencies and risks are noted:
- Stockholder Approval Condition: The effectiveness of the 200,000-share stock option grant is expressly conditioned upon stockholder approval of an amendment to the 2021 Equity Incentive Plan to increase the authorized share pool.
- Indemnification: The Company entered into an Indemnity Agreement to cover Ms. Fedeli against certain expenses, judgments, and fines related to her director role.
Investor Verification Checklist
- Verify the status of the stockholder vote required to approve the amendment to the 2021 Equity Incentive Plan.
- Confirm the vesting schedule of the 200,000 options (25% at one year, remaining 75% quarterly over three years).
- Review the full text of the Director Agreement (Exhibit 99.1) and Indemnity Agreement (Exhibit 99.2) for additional terms.
- Monitor future filings for the impact of the increased board size on corporate governance decisions.